Volume : 10, Issue : 09, September – 2023
Title:
25.REVIEW ON NEW DRUG DEVELOPMENT IN CANCER
Authors :
Miss. Vasa Kalyani, Mr. V. S. Chandrasekaran*, Dr. M. Kishore Babu
Abstract :
The past decade has seen the publication of a number of new proposals for the design of phase 1 trials of anti-cancer agents. As addressed by the recent Food and Drug Administration Critical Path Initiative, tools are urgently needed to increase the speed, efficiency, and cost-effectiveness of drug development for cancer and other diseases Scientists have revealed details of the discovery of a new cancer drug that could be used to treat a range of cancer types, including some blood cancers and solid tumors. Recently, the rapid growth of computational tools for drug discovery, including anticancer therapies, has exhibited a significant and outstanding impact on anticancer drug design and has also provided fruitful insights into the area of cancer therapy. Generally, drug development is a long process because a potential new drug must be identified and then evaluated in preclinical and clinical studies. The discovery of a potential new drug can occur in several different ways. Researchers may identify a new drug by testing numerous compounds in a laboratory panel to assess for any beneficial effects, such as stopping cancer cell growth or killing cancer cells.
KEY WORDS: Drug development, Cancer, Clinical Practice, Pharmacogenomics, Cytochrome.
Cite This Article:
Please cite this article in press V. S. Chandrasekaran et al, Review On New Drug Development In Cancer, Indo Am. J. P. Sci, 2023; 10 (09).
Number of Downloads : 10
References:
1. Dent S F, Eisenhauer EA: Phase I trial design: A renewed methodologies being put into practice. S F Dent et al oncology.1996.
2. Goodman S N, Zahurak ML, Piantadosi S: Some practical improvements in the continual re-assessment method for phase I studies. Stat Med14:1149-1161,1995.
3. Kerr D J, Walkman P, editors. New molecular targets for cancer chemotherapy. BocaRaton (FL): C R C Press;1994.
4. Nyfors A. Methotrexate therapy of psoriasis: an effect and side-effects with particular reference to hepatic changes. A survey. Dan MedBull1980; 27:74–96.
5. World Health Organization. WHO handbook of reporting results of cancer treatment. Geneva: World Health Organization,1979.
6. Mckeown S R. Defining normoxia, hypoxia and hypoxia in tumours-implication for treatment response. 2014; 87: 20130676. [PubMed],[WebofScience®],[GoogleScholar]
7. Adams GE, Dewey DL. Hydrated electrons and radiobiological sensitization. Biochemistry Biophysics Research Community.1963; 12:473–7 [Crossref],[PubMed], [WebofScience ®], google scholar.
8. Tiana M, Villar D, Perez-Guijarro E, et al. A role for insulator elements in the regulation of gene expression response to hypoxia. Nucleic Acids Res2012;40:1916– 27[Crossref], [PubMed], [WebofScience ®], [GoogleScholar]
9. Atkins C, Liu Q, Minthorn E, et al. Characterization of a novel PERK kinase inhibitor with anti-tumor and anti-angiogenic activity. Cancer Research 2013;73:1993– 2002 [Crossref], [PubMed], [WebofScience ®],[GoogleScholar]
10. Weissmann N, Zeller S, Schafer R U,et al. Impact of mitochondria and NADPH oxidases on acute and sustained hypoxic pulmonary vasoconstriction. American Journal Respiratory Cell Molecular Biology. 2006;34:505
11. Casey JR, Grinstein S, Orlowski J. Sensors and regulators of intracellular pH. Nat Rev Mol CellBiol2010;11:50–61 [Crossref],[PubMed], [WebofScience ®], [Google Scholar]
12. Doss M, Zhang JJ, Belanger MJ, et al. Biodistribution and radiation dosimetry of the hypoxia marker 18F- HX4 in monkeys and humans were determined by using whole-body PET/CT. Nuclear Medical Community. 2010;31:1016–24[Crossref], [PubMed], [WebofScience ®], [Google Scholar].
13. Supuran C T . Carbonican hydrases: from biomedical applications of the inhibitors and activators to biotechnological use for CO(2) capture. J Enzyme Inhibition Medical Chemistry. 2013;28;229–32 [Taylor & Francis [Online], [Web ofScience®],[GoogleScholar]
14. Balk will F, Mantovani A. Inflammation and cancer: back to Virchow. Lancet. 2001; 357:539–45.
15. Yamamoto Y, Gaynor R B. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. Journal of Clincal in vest. 2001;107: 135–142.